Sarabjit Sandhu, MD
Psychiatry · Newport Beach, CANPI 1144287186
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 51.3% of the total. Reporting peaked in 2019 at $1,199 and has fallen 97.7% since, to $28 in 2025.
Across 165 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$701
- Lundbeck LLC$133
- Takeda Pharmaceuticals U.S.A., Inc.$96
- Johnson & Johnson$45
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$44
- plus $146 from 8 others
What the payments were for
- Food & beverage$2,394100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $1,228 |
| Sunovion Pharmaceuticals Inc. | 59 | $701 |
| Lundbeck LLC | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $96 |
| Johnson & Johnson | 2 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| OWP Pharmaceuticals, Inc. | 1 | $25 |
| Indivior Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
How this compares
$2,394 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 235 | $829,461 |
| AristadaAripiprazole Lauroxil | 53 | $173,447 |
| VraylarCariprazine Hcl | 111 | $112,494 |
| PerserisRisperidone | 31 | $82,878 |
| Lurasidone Hcl | 411 | $80,481 |
| Clozapine OdtClozapine | 101 | $72,128 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 684 | $62,611 |
| XifaxanRifaximin | 29 | $45,457 |
| Divalproex Sodium ErDivalproex Sodium | 624 | $43,329 |
| IngrezzaValbenazine Tosylate | 15 | $41,422 |
| Clozapine | 386 | $40,343 |
| CaplytaLumateperone Tosylate | 35 | $29,456 |
| RexultiBrexpiprazole | 16 | $28,644 |
| TrulicityDulaglutide | 53 | $27,637 |
| Olanzapine | 614 | $26,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Xarelto | $45 | $836,302259 claims |
| AbbVieVraylar | $1,228 | $112,494111 claims |
| Indivior Inc.Perseris | $22 | $82,87831 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $96 | $33,018103 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $44 | $29,45635 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $14 | $28,64416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Newport Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.